Gilead Sciences, Inc (NASDAQ: GILD) shares took a jolt in the after-hours session Tuesday as it announced its application for filgotinib, an investigational treatment for moderately to severely active rheumatoid arthritis (RA) didn’t get the go-ahead from the United States Food and Drug Administration.What Happened: The biopharmaceutical company received a complete response letter (CRL) from the FDA that said the review cycle for an application is complete and that the application isn’t ready for approval in its present form.Gilead is the market authorization holder for filgotinib in the U.S. as well as for the potential commercialization of the drug in …read more
Source:: Yahoo Finance
